Method of producing sub-micron particles of biologically active agents and uses thereof

• US 6,284,283 B1
• Filed: 10/21/1999
• Issued: 09/04/2001
• Est. Priority Date: 10/21/1999
• Status: Expired due to Term

• Current Assignee: Alkermes Controlled Therapeutics Inc. II (Alkermes plc)
• Original Assignee: Alkermes Controlled Therapeutics Inc. II (Alkermes plc)
• Inventors: Costantino, Henry R., Jaworowicz, Warren E., Tracy, Mark A., Beganski, Christopher P.
• Primary Examiner(s): AZPURU, CARLOS A
• Application Number:
  US09/422,751
• Time in Patent Office: 684 Days
• Field of Search: 424/501, 424/502, 264/4.1, 264/4.33, 264/4.6, 428/402.21
• US Class Current: 424/501
• CPC Class Codes: A61K 9/1688 resulting in pure drug agglomerate optionally containing up to 5% of excipient
• CPC Class Codes: A61K 9/1694 resulting in granules or microspheres of the matrix type containing more than 5% of excipient
• CPC Class Codes: Y10S 977/906 Drug delivery
• CPC Class Codes: Y10T 428/2985 Solid-walled microcapsule from synthetic polymer

Abstract

Submicron particles of a biologically active agent are prepared by atomizing using multifluid atomization a dispersed system comprising at least one biologically active agent and at least one solvent to produce droplets, freezing the droplets to produce frozen droplets, lyophilizing the frozen droplets to obtain microstructures capable of being further fragmented into submicron particles by techniques such as probe sonication. The submicron particles can be incorporated into sustained release compositions having a reduced initial release of biologically active agent. The sustained release compositions can be administered to a human or animal.

Claims

1. A method for preparing submicron particles of a biologically active agent comprising the steps of:

(a) atomizing using multifluid atomization a dispersed system comprising at least one biologically active agent and at least one solvent at a mass flow ratio of about 0.30 or greater to produce droplets;

(b) freezing the droplets to produce frozen droplets;

(c) removing the solvent from the frozen droplets to produce friable microstructures;

(d) forming a dispersion of the friable microstructures with at least one non-solvent for the biologically active agent; and

(e) fragmenting the dispersed friable microstructures into submicron particles of biologically active agent.

2. The method of claim 1 wherein freezing is achieved by contacting the droplets with a cryogenic liquid.

3. The method of claim 2 wherein the cryogenic liquid is liquid nitrogen.

4. The method of claim 1 wherein the solvent is removed by lyophilization.

5. The method of claim 4 wherein lyophilization is conducted at a temperature below the lowest Tg of the frozen droplets.

6. The method of claim 1 wherein fragmentation is accomplished by homogenization, milling, sonication or a combination thereof.

7. The method of claim 6 wherein fragmentation is accomplished by sonication.

8. The method of claim 1 wherein the dispersion of friable microstructures further comprises at least one biocompatible polymer dissolved therein.

9. The method of claim 1 wherein the submicron particles have a volume median particle size of less than 1 micron, measured by laser diffraction.

10. The method of claim 1 wherein the biologically active agent is a protein or peptide.

11. The method of claim 10 wherein the protein is complexed to a stabilizing metal cation.

12. The method of claim 11 wherein said stabilizing metal cation is selected from the group consisting of Zn⁺², Ca⁺², Cu⁺², Mg⁺², K⁺ and any combination thereof.

13. The method of claim 12 wherein the stabilizing metal cation is Zn⁺².

14. The method of claim 13 wherein the protein is recombinant human growth hormone.

15. The method of claim 1 wherein the dispersed system further comprises a metal cation component.

16. The method of claim 15 wherein the metal cation component is selected from the group consisting of Mg(OH)₂, MgCO₃, CaCO₃, ZnCO₃, Mg(OAc)₂, Zn(OAc)₂, ZnSO₄, MgCl₂, ZnCl₂, MgSO₄, zinc citrate and magnesium citrate.

17. A method for preparing a composition for the sustained release of biologically active agent comprising the steps of:

a) atomizing using multifluid atomization a dispersed system comprising at least one biologically active agent and at least one solvent at a mass flow ratio of about 0.30 or greater to produce droplets;

b) freezing the droplets to produce frozen droplets;

c) removing the solvent from the frozen droplets to produce friable microstructures;

d) dispersing the friable microstructures in at least one non-solvent for the biologically active agent;

e) fragmenting the dispersed friable microstructures to produce submicron particles of the biologically active agent;

f) providing a suspension comprising the submicron particles of the biologically active agent, at least one biocompatible polymer and at least one polymer solvent; and

g) removing the polymer solvent to form a solid polymer/active agent matrix.

18. The method of claim 17 further comprising the steps of:

a) forming droplets of the polymer/active agent suspension;

b) freezing the droplets of the polymer/active agent suspension wherein steps a) and b) are performed prior to removing the polymer solvent; and

c) removing the polymer solvent by extraction with an extraction solvent.

19. The method of claim 17 wherein the submicron particles have a volume median particle size of less than 1 micron, measured by laser diffraction.

20. The method of claim 17 wherein the biologically active agent is present in the suspension at a concentration of from about 0.01 to about 50% w/w of the combined weight of polymer and biologically active agent.

21. The method of claim 20 wherein the biologically active agent is present at a concentration of about 0.01 to 30% w/w of the combined weight of the polymer and biologically active agent.

22. The method of claim 17 wherein the biologically active agent is a protein or peptide.

23. The method of claim 22 wherein the biologically active agent is complexed to a stabilizing metal cation.

24. The method of claim 23 wherein said stabilizing metal cation is selected from the group consisting of Zn⁺², Ca⁺², Cu⁺², Mg⁺², K⁺ and any combination thereof.

25. The method of claim 24 wherein said stabilizing metal cation is Zn⁺.

26. The method of claim 22 wherein the protein is human growth hormone.

27. The method of claim 26 wherein the human growth hormone is complexed to Zn⁺².

28. The method of claim 17 wherein the biocompatible polymer is biodegradable.

29. The method of claim 28 wherein the biodegradable polymer is selected from the group consisting of poly(lactide)s, poly(glycolide)s, poly(lactide-coglycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, poly(caprolactone), polycarbonates, polyesteraniides, polyanhydrides, poly(amino acid)s, poly(ortho ester)s, polycyanoacrylates, polyamides, polyacetals, poly(ether ester)s, copolymers of poly(ethylene glycol) and poly(ortho ester)s, poly(dioxanone)s, poly(alkylene alkylate)s, biodegradable polyurethanes, blends and copolymers thereof.

30. The method of claim 29 wherein said polymer is poly(lactide-co-glycolide).

31. The method of claim 17 wherein the biocompalible polymer is non-biodegradable.

32. The method of claim 17 wherein the polymer solvent is methylene chloride, chloroform, acetone, ethyl acetate, methyl acetate, dimethylsulfoxide, hexafluoroisopropanol or any combinations thereof.

33. The method of claim 17 wherein the dispersed system further comprises a metal cation component which modulates the release of the biologically active agent from the composition for sustained release.

34. The method of claim 33 wherein the metal cation component is selected from the group consisting of Mg(OH)₂, MgCO₃, CaCO₃, ZnCO₃, Mg(OAc)₂, Zn(OAc)₂, ZnSO₄, MgCl₂, ZnCl₂, MgSO₄, zinc citrate and magnesium citrate.

35. The method of claim 17 wherein the suspension further comprises a metal cation component which modulates the release of the biologically active agent from the composition for sustained release.

36. A method for providing a therapeutically, prophylactically or diagnostically effective amount of a biologically active agent to a subject in need thereof for a sustained period comprising administering to the subject a dose of the sustained release composition prepared according to claim 17.